119 related articles for article (PubMed ID: 38219610)
21. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
22. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
23. Construction and validation of a nomogram for hepatocellular carcinoma patients based on HCC-GRIm score.
Yu X; Yang R; He Z; Li K; Zeng P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12013-12024. PubMed ID: 37421461
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of chemotherapy according to
Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
[TBL] [Abstract][Full Text] [Related]
25. Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis.
Tian S; Cao Y; Duan Y; Liu Q; Peng P
Front Oncol; 2021; 11():737283. PubMed ID: 34917499
[TBL] [Abstract][Full Text] [Related]
26. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
27. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
28. Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer.
Dai D; Liu L; Huang H; Chen S; Chen B; Cao J; Luo X; Wang F; Luo R; Liu J
Front Oncol; 2021; 11():590414. PubMed ID: 33718143
[TBL] [Abstract][Full Text] [Related]
29. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
van Zyl B; Tang D; Bowden NA
Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic factors and construction of a nomogram for patients with relapse/refractory adult-onset Still's disease.
Yin R; Wang G; Yang X; Zhang L; Wang S; Li T; Liu S
Clin Rheumatol; 2021 Oct; 40(10):3951-3960. PubMed ID: 34002352
[TBL] [Abstract][Full Text] [Related]
33. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
34. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
[TBL] [Abstract][Full Text] [Related]
35. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK
Eur J Cancer; 2021 Sep; 154():190-200. PubMed ID: 34293664
[TBL] [Abstract][Full Text] [Related]
36. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
37. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
38. Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI.
Lu J; Cai S; Wang F; Wu PY; Pan X; Qiang J; Li H; Zeng M
Acad Radiol; 2023 Sep; 30(9):1823-1831. PubMed ID: 36587996
[TBL] [Abstract][Full Text] [Related]
39. Preoperative prediction of miliary changes in the small bowel mesentery in advanced high-grade serous ovarian cancer using MRI radiomics nomogram.
Guo Q; Lin Z; Lu J; Li R; Wu L; Deng L; Qiang J; Wu X; Gu Y; Li H
Abdom Radiol (NY); 2023 Mar; 48(3):1119-1130. PubMed ID: 36651979
[TBL] [Abstract][Full Text] [Related]
40. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]